BNTC
NASDAQBenitec Biopharma Inc.
Price$10.47-0.08 (-0.81%)
02:00 PM07:45 PM
News · 26 weeks25+133%
2025-12-072026-05-31
Mix1390d
- Other4(31%)
- SEC Filings4(31%)
- Leadership2(15%)
- Insider2(15%)
- Analyst1(8%)
Latest news
25 items- SECBenitec Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Benitec Biopharma Inc. (0001808898) (Filer)
- INSIDERSEC Form 4 filed by Director Friedman David Matthew4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 3 filed by new insider Friedman David Matthew3 - Benitec Biopharma Inc. (0001808898) (Issuer)
- SECSEC Form 10-Q filed by Benitec Biopharma Inc.10-Q - Benitec Biopharma Inc. (0001808898) (Filer)
- SECBenitec Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Benitec Biopharma Inc. (0001808898) (Filer)
- PRBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational UpdateLate-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomesBB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15Advancement of Cohort 2 enrollment continues as Patient 1 and Patient 2 were both safely treated with high dose B
- ANALYSTEvercore ISI initiated coverage on Benitec Biopharma with a new price targetEvercore ISI initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $25.00
- PRBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA in
- PRPureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st
- PRSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsDr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company
- SECAmendment: SEC Form 10-K/A filed by Benitec Biopharma Inc.10-K/A - Benitec Biopharma Inc. (0001808898) (Filer)
- PRBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l
- PRBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage th
- PRBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-dir
- PRBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- - An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to
- SECBenitec Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form 10-Q filed by Benitec Biopharma Inc.10-Q - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form EFFECT filed by Benitec Biopharma Inc.EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form S-3 filed by Benitec Biopharma Inc.S-3 - Benitec Biopharma Inc. (0001808898) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
- INSIDERSEC Form 4 filed by Director Mates Sharon4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- PRBenitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301 HAYWARD, Calif., Jan. 11
- INSIDERDirector Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERDirector Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
BNTC FAQ
7 questionsWhat does Benitec Biopharma Inc. do?
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.Where does BNTC stock trade?
Benitec Biopharma Inc. (BNTC) is listed on NASDAQ.What sector and industry is BNTC in?
Benitec Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Benitec Biopharma Inc. go public?
Benitec Biopharma Inc. (BNTC) completed its IPO in 2015.What are analysts saying about BNTC?
Benitec Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $2500.00 price target on 2026-05-12. Recent price targets range from $1300.00 to $3500.00.What companies are similar to BNTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BNTC side-by-side with any of them on Quantisnow.How can I track BNTC on Quantisnow?
Quantisnow aggregates Benitec Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNTC to receive live email and push alerts on every new disclosure.